Li Zhaohui, Yang Yanyan, Zong Jinbao, Zhang Bei, Li Xiaolu, Qi Hongzhao, Yu Tao, Li Yongxin
Department of Vascular Surgery, the Affiliated Hospital of Qingdao University, Qingdao, 266400, China.
Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China.
Acta Pharm Sin B. 2025 Feb;15(2):792-808. doi: 10.1016/j.apsb.2024.12.029. Epub 2024 Dec 31.
Atherosclerosis, a chronic inflammatory disease, is markedly influenced by both immune and inflammatory reactions throughout its progression. Dendritic cells, as pivotal antigen-presenting entities, play a crucial role in the initiation of immune responses and the preservation of immunological homeostasis. Accumulating data indicates that dendritic cells are present in healthy arteries and accumulate significantly in atherosclerotic plaques. Novel immunotherapeutic approaches and vaccination protocols have yielded substantial clinical advancements in managing chronic inflammatory diseases, with dendritic cell-centric modalities emerging for atherosclerotic management. In this review, we delineate the essential functions and underlying mechanisms of dendritic cells and their subsets in the modulation of atherosclerotic inflammation and immune responses. We underscore the immense promise of dendritic cell-based immunotherapeutic strategies, including vaccines and innovative combinations with nanotechnological drug delivery platforms for atherosclerosis treatment. We also discuss the challenges associated with dendritic cell immunotherapy and provide perspectives on the future direction of this field.
动脉粥样硬化是一种慢性炎症性疾病，在其整个发展过程中受到免疫和炎症反应的显著影响。树突状细胞作为关键的抗原呈递细胞，在免疫反应的启动和免疫稳态的维持中发挥着至关重要的作用。越来越多的数据表明，树突状细胞存在于健康动脉中，并在动脉粥样硬化斑块中大量积聚。新型免疫治疗方法和疫苗接种方案在慢性炎症性疾病的管理方面取得了重大临床进展，以树突状细胞为中心的治疗方式也应运而生用于动脉粥样硬化的管理。在这篇综述中，我们阐述了树突状细胞及其亚群在调节动脉粥样硬化炎症和免疫反应中的基本功能和潜在机制。我们强调了基于树突状细胞的免疫治疗策略的巨大前景，包括疫苗以及与纳米技术药物递送平台的创新组合用于动脉粥样硬化的治疗。我们还讨论了树突状细胞免疫治疗相关的挑战，并对该领域的未来方向提供了展望。
